The current state of oligometastatic and oligoprogressive non-small cell lung cancer

Vasu Tumati, Puneeth Iyengar

Research output: Contribution to journalReview articlepeer-review

20 Scopus citations


Oligometastatic disease is defined as an intermediate state between localized and widespread metastatic disease. Given that in the oligometastatic state gross tumors represent the full extent of disease, there may be a role for curative local therapy despite metastatic disease. As nearly 60% of patients with nonsmall cell lung cancer (NSCLC) present with metastatic disease and another 45% of patients with initially localized disease will ultimately develop distant metastases, NSCLC represents a prime disease for aggressive intervention. In this review, the definition, prognostic factors, patient selection, rationale and evidence for treatment of oligoprogressive and oligometastatic NSCLC is discussed, including recent prospective trials and future directions.

Original languageEnglish (US)
Pages (from-to)S2537-S2544
JournalJournal of Thoracic Disease
StatePublished - Aug 1 2018


  • Metastasectomy
  • Non-small cell lung cancer (NSCLC)
  • Oligometastases
  • Oligoprogressive
  • Stereotactic ablative radiotherapy (SABR)
  • Stereotactic body radiation therapy (SBRT)

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine


Dive into the research topics of 'The current state of oligometastatic and oligoprogressive non-small cell lung cancer'. Together they form a unique fingerprint.

Cite this